Updates are available Correction dated 2021-11-15
Click to view Correction: https://doi.org/10.1038/s41578-021-00400-1
-
Authors
Hou, Xucheng
Zaks, Tal
Langer, Robert http://orcid.org/0000-0003-4255-0492
Dong, Yizhou http://orcid.org/0000-0001-5786-0659
- License Information
-
More Information
Article History
Accepted: 19 July 2021
First Online: 10 August 2021
Change Date: 15 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41578-021-00400-1
Competing interests
: Y.D. is a scientific advisory board member of Oncorus, Inc. and serves as a consultant of Rubius Therapeutics. T.Z. is an employee of Moderna, Inc. R.L. is a founding scientific advisory board member of Alnylam and a founder and board member of Moderna, Inc. A list of entities with which R.L. is involved, compensated or uncompensated is provided in the InternalRef removed. X.H. declares no competing interests.
Free to read: This content has been made available to all.
